Uploaded December 2025 | Updated November 2026, 6 hours ago
Presented By: Mark Mondrinos, PhD
Speaker Biography: Mark Mondrinos received a B.Sc. degree in Chemical Engineering from the FAMU-FSU college of engineering and a B.Sc. degree in Biochemistry, with minors in Mathematics and Biological Sciences, from Florida State University in 2002. He obtained a Ph.D. in Biomedical Engineering from Drexel University in 2011. Dr. Mondrinos received the award for ‘Best Dissertation in the Physical and Life Sciences’ for his PhD studies on the development of vascularized pulmonary organoids in vitro. He then received two years of NIH T32-funded postdoctoral training at Temple University School of Medicine, working on animal models of sepsis and clinical studies on inflammatory lung injury that revealed protein kinase C-delta as a targetable inflammatory kinase for lung protection. Dr. Mondrinos was then a postdoctoral scholar for five years in the Department of Bioengineering and the NSF Center for Engineering Mechanobiology at the University of Pennsylvania, where he developed human organ chips and microphysiological systems for diverse applications in modeling normal physiological processes and diseases. Since joining the Tulane Biomedical Engineering faculty in 2019, Dr. Mondrinos’ lab has endeavored to develop complex organ chip systems for modeling advanced cancer pathophysiology, outer retinal pathophysiology, and diseases of the airways and pulmonary interstitium, among other applications. The Mondrinos lab integrates engineering with preclinical science, for example by using these models for investigation of phytochemicals as anti-cancer agents and the development of biological sex-matched human tissue and organ models to enhance and accelerate discovery and drug screening for myriad diseases involving pathology of the vasculature and interstitium.
Webinar: New Approach Methodologies: Microphysiological Systems for Preclinical Research
Webinar Abstract: So-called new approach methodologies (NAMs) including human cell-based microphysiological systems (MPS) are poised to revolutionize preclinical science and improve the success rate of candidate therapeutics in clinical trials. To achieve these goals, it will be critical to capture aspects of individual physiological differences such as biological sex and hormone status in microphysiological systems and other NAMs. Sex-specific cell culture methods and MPS can enhance our understanding of how biological sex influences health and disease. Our laboratory has demonstrated baseline sex differences in numerous 2D culture and MPS bioassays when a common cell culture medium is used for both sexes. To address this limitation, we developed sex-specific culture methods based on culturing female cells with estradiol and male cells with dihydrotestosterone, the concentrations of which can be tuned to yield sex-equivalent baselines in select 2D and MPS bioassays. This talk will emphasize the application of these culture methods to create sex-specific MPS models of diabetic retinopathy. Sex-matched combinations of primary human retinal microvascular endothelial cells and ocular fibroblasts were used to construct MPS models of an endothelial barrier and vascular beds. Estradiol protected against pathological changes induced by diabetic culture conditions, such as increased barrier permeability and basement membrane thickening, in female but not male models. Dihydrotestosterone failed to protect against pathological changes in both female and male models. These results are compatible with clinical observations of increased incidence and severity in male patients. Further refinement of sex-specific MPS will enable the investigation of sex-based precision therapies that target sex hormone signaling in diabetic retinopathy and other diseases.
Learning Objectives:
1. Describe how new approach methodologies (NAMs) and microphysiological systems (MPS) can improve preclinical research and therapeutic development.
2. Differentiate the impact of sex-specific cell culture methods on baseline responses in 2D and MPS bioassays.
3. Interpret findings from sex-specific MPS models of diabetic retinopathy to evaluate implications for precision therapies.
Earn PACE Credits: 1. Make sure you’re a registered member of Labroots (labroots.com/virtual-event/cell-bio-2025) 2. Watch the webinar on YouTube or on the Labroots Website (labroots.com/virtual-event/cell-bio-2025/agenda) 3. Click Here to get your PACE credits (Expiration date – 9/17/2026): (labroots.com/virtual-event/cell-bio-2025/continuing-education-credits) This link will be located in the CMS in the webinar CE tab – please enable third party PACE link
Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc
Presented By: Mark Mondrinos, PhD
Speaker Biography: Mark Mondrinos received a B.Sc. degree in Chemical Engineering from the FAMU-FSU college of engineering and a B.Sc. degree in Biochemistry, with minors in Mathematics and Biological Sciences, from Florida State University in 2002. He obtained a Ph.D. in Biomedical Engineering from Drexel University in 2011. Dr. Mondrinos received the award for ‘Best Dissertation in the Physical and Life Sciences’ for his PhD studies on the development of vascularized pulmonary organoids in vitro. He then received two years of NIH T32-funded postdoctoral training at Temple University School of Medicine, working on animal models of sepsis and clinical studies on inflammatory lung injury that revealed protein kinase C-delta as a targetable inflammatory kinase for lung protection. Dr. Mondrinos was then a postdoctoral scholar for five years in the Department of Bioengineering and the NSF Center for Engineering Mechanobiology at the University of Pennsylvania, where he developed human organ chips and microphysiological systems for diverse applications in modeling normal physiological processes and diseases. Since joining the Tulane Biomedical Engineering faculty in 2019, Dr. Mondrinos’ lab has endeavored to develop complex organ chip systems for modeling advanced cancer pathophysiology, outer retinal pathophysiology, and diseases of the airways and pulmonary interstitium, among other applications. The Mondrinos lab integrates engineering with preclinical science, for example by using these models for investigation of phytochemicals as anti-cancer agents and the development of biological sex-matched human tissue and organ models to enhance and accelerate discovery and drug screening for myriad diseases involving pathology of the vasculature and interstitium.
Webinar: New Approach Methodologies: Microphysiological Systems for Preclinical Research
Webinar Abstract: So-called new approach methodologies (NAMs) including human cell-based microphysiological systems (MPS) are poised to revolutionize preclinical science and improve the success rate of candidate therapeutics in clinical trials. To achieve these goals, it will be critical to capture aspects of individual physiological differences such as biological sex and hormone status in microphysiological systems and other NAMs. Sex-specific cell culture methods and MPS can enhance our understanding of how biological sex influences health and disease. Our laboratory has demonstrated baseline sex differences in numerous 2D culture and MPS bioassays when a common cell culture medium is used for both sexes. To address this limitation, we developed sex-specific culture methods based on culturing female cells with estradiol and male cells with dihydrotestosterone, the concentrations of which can be tuned to yield sex-equivalent baselines in select 2D and MPS bioassays. This talk will emphasize the application of these culture methods to create sex-specific MPS models of diabetic retinopathy. Sex-matched combinations of primary human retinal microvascular endothelial cells and ocular fibroblasts were used to construct MPS models of an endothelial barrier and vascular beds. Estradiol protected against pathological changes induced by diabetic culture conditions, such as increased barrier permeability and basement membrane thickening, in female but not male models. Dihydrotestosterone failed to protect against pathological changes in both female and male models. These results are compatible with clinical observations of increased incidence and severity in male patients. Further refinement of sex-specific MPS will enable the investigation of sex-based precision therapies that target sex hormone signaling in diabetic retinopathy and other diseases.
Learning Objectives:
1. Describe how new approach methodologies (NAMs) and microphysiological systems (MPS) can improve preclinical research and therapeutic development.
2. Differentiate the impact of sex-specific cell culture methods on baseline responses in 2D and MPS bioassays.
3. Interpret findings from sex-specific MPS models of diabetic retinopathy to evaluate implications for precision therapies.
Earn PACE Credits: 1. Make sure you’re a registered member of Labroots (labroots.com/virtual-event/cell-bio-2025) 2. Watch the webinar on YouTube or on the Labroots Website (labroots.com/virtual-event/cell-bio-2025/agenda) 3. Click Here to get your PACE credits (Expiration date – 9/17/2026): (labroots.com/virtual-event/cell-bio-2025/continuing-education-credits) This link will be located in the CMS in the webinar CE tab – please enable third party PACE link
Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc










